  <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"><html xmlns:xalan-nodeset="org.apache.xalan.xslt.extensions.Nodeset" xmlns:java="http://xml.apache.org/xslt/java" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:pto="urn:us:gov:doc:uspto:enterprise" xmlns:bf="http://www.uspto.gov/bf" xmlns:xi="http://www.w3.org/2001/XInclude" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
   <head>
      <title>2423-</title>
      <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
</head>
      <li><a href="index.html">Manual of Patent Examining Procedure</a></li>
      <li><a href="mpep-2400.html"><span>Chapter 2400</span></a></li>
      <li><span>Section 2423</span></li>  </ul>  </div>
      <div id="yui-main">
         <div class="yui-b">
            <div class="yui-g">  <div xmlns:bf="http://www.uspto.gov/bf" id="article">
               <div>
                  <div xmlns="" class="Section" id="d0e245494">
                     <h1 class="page-title">2423
                        &nbsp;&nbsp;
                        Symbols and Format To Be Used for Nucleotide and/or Amino Acid
                        Sequence Data  [R-08.2012]
                     </h1>
                     <div id="d0e245498" class="CFR">
                        <h4 class="CFR"><i>37&nbsp;C.F.R.&nbsp;1.822 &nbsp;
                              
                              
                              
                              Symbols and format to be used for nucleotide and/or amino acid
                              sequence data.</i></h4>
                        <ul style="list-style-type: none;">
                           <li id="d0e245503" class="nobull">(a) The symbols and format to
                              be used for nucleotide and/or amino acid sequence data shall conform to the
                              requirements of paragraphs (b) through (e) of this section.
                           </li>
                           <li id="d0e245507" class="nobull">(b) The code for representing
                              the nucleotide and/or amino acid sequence characters shall conform to the code
                              set forth in the tables in WIPO Standard ST.25 (1998), Appendix 2, Tables 1 and
                              3. This incorporation by reference was approved by the Director of the Federal
                              Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies of ST.25
                              may be obtained from the World Intellectual Property Organization; 34 chemin
                              des Colombettes; 1211 Geneva 20 Switzerland. Copies of ST.25 may be inspected
                              at the Patent Search Room; Crystal Plaza 3, Lobby Level; 2021 South Clark
                              Place; Arlington, VA 22202. Copies may also be inspected at the Office of the
                              Federal Register, 800 North Capitol Street, NW, Suite 700, Washington, DC. No
                              code other than that specified in these sections shall be used in nucleotide
                              and amino acid sequences. A modified base or modified or unusual amino acid may
                              be presented in a given sequence as the corresponding unmodified base or amino
                              acid if the modified base or modified or unusual amino acid is one of those
                              listed in WIPO Standard ST.25 (1998), Appendix 2, Tables 2 and 4, and the
                              modification is also set forth in the Feature section. Otherwise, each
                              occurrence of a base or amino acid not appearing in WIPO Standard ST.25 (1998),
                              Appendix 2, Tables 1 and 3, shall be listed in a given sequence as “n” or
                              “Xaa,” respectively, with further information, as appropriate, given in the
                              Feature section, preferably by including one or more feature keys listed in
                              WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6.
                           </li>
                           <li id="d0e245511" class="nobull">(c) <i>Format representation of nucleotides.</i> (1) A
                              nucleotide sequence shall be listed using the lower-case letter for
                              representing the one-letter code for the nucleotide bases set forth in WIPO
                              Standard ST.25 (1998), Appendix 2, Table 1.
                              <ul style="list-style-type: none;">
                                 <li id="" class="nobull">
                                    <p id=""></p>
                                 </li>
                                 <li id="d0e245517" class="nobull">(2) The bases in a
                                    nucleotide sequence (including introns) shall be listed in groups of 10
                                    bases except in the coding parts of the sequence. Leftover bases, fewer
                                    than 10 in number, at the end of noncoding parts of a sequence shall be
                                    grouped together and separated from adjacent groups of 10 or 3 bases by a
                                    space.
                                 </li>
                                 <li id="d0e245521" class="nobull">(3) The bases in the
                                    coding parts of a nucleotide sequence shall be listed as triplets
                                    (codons). The amino acids corresponding to the codons in the coding parts
                                    of a nucleotide sequence shall be typed immediately below the
                                    corresponding codons. Where a codon spans an intron, the amino acid
                                    symbol shall be typed below the portion of the codon containing two
                                    nucleotides.
                                 </li>
                                 <li id="d0e245525" class="nobull">(4) A nucleotide sequence
                                    shall be listed with a maximum of 16 codons or 60 bases per line, with a
                                    space provided between each codon or group of 10 bases.
                                 </li>
                                 <li id="d0e245529" class="nobull">(5) A nucleotide sequence
                                    shall be presented, only by a single strand, in the 5 to 3 direction,
                                    from left to right.
                                 </li>
                                 <li id="d0e245533" class="nobull">(6) The enumeration of
                                    nucleotide bases shall start at the first base of the sequence with
                                    number 1. The enumeration shall be continuous through the whole sequence
                                    in the direction 5 to 3. The enumeration shall be marked in the right
                                    margin, next to the line containing the one-letter codes for the bases,
                                    and giving the number of the last base of that line.
                                 </li>
                                 <li id="d0e245537" class="nobull">(7) For those nucleotide
                                    sequences that are circular in configuration, the enumeration method set
                                    forth in paragraph (c)(6) of this section remains applicable with the
                                    exception that the designation of the first base of the nucleotide
                                    sequence may be made at the option of the applicant.
                                 </li>
                              </ul>
                           </li>
                           <li id="d0e245541" class="nobull">(d) <i>Representation of amino acids.</i> (1) The
                              amino acids in a protein or peptide sequence shall be listed using the
                              three-letter abbreviation with the first letter as an upper case character, as
                              in WIPO Standard ST.25 (1998), Appendix 2, Table 3.
                              <ul style="list-style-type: none;">
                                 <li id="" class="nobull">
                                    <p id=""></p>
                                 </li>
                                 <li id="d0e245547" class="nobull">(2) A protein or peptide
                                    sequence shall be listed with a maximum of 16 amino acids per line, with
                                    a space provided between each amino acid.
                                 </li>
                                 <li id="d0e245551" class="nobull">(3) An amino acid
                                    sequence shall be presented in the amino to carboxy direction, from left
                                    to right, and the amino and carboxy groups shall not be presented in the
                                    sequence.
                                 </li>
                                 <li id="d0e245555" class="nobull">(4) The enumeration of
                                    amino acids may start at the first amino acid of the first mature
                                    protein, with the number 1. When presented, the amino acids preceding the
                                    mature protein, <i>e.g.</i>, pre-sequences,
                                    pro-sequences, pre-pro-sequences and signal sequences, shall have
                                    negative numbers, counting backwards starting with the amino acid next to
                                    number 1. Otherwise, the enumeration of amino acids shall start at the
                                    first amino acid at the amino terminal as number 1. It shall be marked
                                    below the sequence every 5 amino acids. The enumeration method for amino
                                    acid sequences that is set forth in this section remains applicable for
                                    amino acid sequences that are circular in configuration, with the
                                    exception that the designation of the first amino acid of the sequence
                                    may be made at the option of the applicant.
                                 </li>
                                 <li id="d0e245562" class="nobull">(5) An amino acid
                                    sequence that contains internal terminator symbols (<i>e.g.</i>, “Ter”, “*”, or “.”, etc.) may not be
                                    represented as a single amino acid sequence, but shall be presented as
                                    separate amino acid sequences.
                                 </li>
                              </ul>
                           </li>
                           <li id="d0e245569" class="nobull">(e) A sequence with a gap or
                              gaps shall be presented as a plurality of separate sequences, with separate
                              sequence identifiers, with the number of separate sequences being equal in
                              number to the number of continuous strings of sequence data. A sequence that is
                              made up of one or more noncontiguous segments of a larger sequence or segments
                              from different sequences shall be presented as a separate
                              sequence.
                           </li>
                        </ul>
                     </div>
                     <p id="d0e245573">Tables 1-6 of WIPO Standard ST.25
                        (1998), Appendix 2, are reproduced in <b><a href="s2422.html#d0e242638">MPEP §
                              2422</a></b>.
                     </p>
                     <div class="Section">
                        <h1 class="page-title" id="d0e245579">2423.01
                           &nbsp;&nbsp;Format and Symbols To Be Used in Sequence Listings  [R-08.2012]
                        </h1>
                        <p id="d0e245587"><b><a href="mpep-9020-appx-r.html#d0e333753">37
                                 CFR 1.822</a></b> sets forth the format and symbols to be used for listing
                           nucleotide and/or amino acid sequence data. The codes for representing the nucleotide
                           and/or amino acid characters in the sequences are set forth in the tables of WIPO
                           Standard ST.25 (1998), Appendix 2, Tables 1 and 3. See <b><a href="s2422.html#d0e242638">MPEP
                                 §&nbsp;2422</a></b>. No other symbols shall be used in nucleotide and amino
                           acid sequences. The “modified base” and “modified and unusual amino acid” codes
                           appearing in WIPO Standard ST.25 (1998), Appendix 2, Tables 2 and 4 (see
                           <b><a href="mpep-9020-appx-r.html#d0e333753">37
                                 CFR 1.822</a></b> and <b><a href="s2422.html#d0e242638">MPEP § 2422</a></b>) are not
                           to be set forth in the sequences recited in the Sequence Listing. However, “modified
                           base” or “modified and unusual amino acid” codes may be used in the written description
                           and/or drawing portions of the specification. To properly enter notations for modified
                           codes in the Sequence Listing, the Feature section of the Sequence Listing should be
                           used. That is, a modified base or amino acid may be presented in a given sequence as the
                           corresponding unmodified base or amino acid if the modified base or amino acid is one of
                           those listed in WIPO Standard ST.25 (1998), Appendix 2, Table 2 or 4 and the
                           modification is also set forth in the Feature section of the Sequence Listing.
                           Otherwise, all bases or amino acids not appearing in WIPO Standard ST.25 (1998),
                           Appendix 2, Table 1 or 3 must be listed in a given sequence as “n” or “Xaa,”
                           respectively, with further information given in the Feature section of the “Sequence
                           Listing.” See <b><a href="mpep-9020-appx-r.html#d0e333837">37 CFR 1.823(b)</a></b>.
                        </p>
                        <p id="d0e245604">In <b><a href="mpep-9020-appx-r.html#d0e333753">37 CFR
                                 1.822(b)</a></b> and <b><a href="mpep-9020-appx-r.html#d0e333753">37 CFR 1.822(d)</a></b>, the use of
                           three-letter codes for amino acids is required. The use of the three-letter codes for
                           amino acids is preferred over the one-letter codes from the perspective of facilitating
                           the examiner’s review of the application papers, including the “Sequence Listing”, and
                           the public’s, as well as the examiner’s, use of the printed patents. The three-letter
                           codes must be presented using the upper case for the first character and lower case for
                           the remaining two characters.
                        </p>
                        <p id="d0e245613"><b><a href="mpep-9020-appx-r.html#d0e333753">37
                                 CFR 1.822(c)</a></b> through (e) set forth the format for presenting
                           sequence data. These paragraphs set forth the manner in which the characters in
                           sequences are to be grouped, spaced, presented and numbered. 
                        </p>
                     </div>
                     <div class="Section">
                        <h1 class="page-title" id="d0e245618">2423.02
                           &nbsp;&nbsp;Depiction of Coding Regions  [R-08.2012]
                        </h1>
                        <p id="d0e245622">If applicant chooses to depict
                           coding regions, <b><a href="mpep-9020-appx-r.html#d0e333753">37&nbsp;CFR 1.822(c)(3)</a></b> requires the
                           amino acids corresponding to the codons in the coding parts of a nucleotide sequence to
                           be typed immediately below the corresponding codons. Further, in <b><a href="mpep-9020-appx-r.html#d0e333753">37 CFR
                                 1.822(c)(3)</a></b>, the situation in which a codon spans an intron has
                           been addressed. In those situations, the “amino acid symbol shall be typed below the
                           portion of the codon containing two nucleotides.” This requirement clarifies the
                           representation of an amino acid that corresponds to a codon that spans an
                           intron.
                        </p>
                        <p id="d0e245631">It should be noted that the sequence
                           rules do not, in any way, require the depiction of coding regions or the amino acids
                           corresponding to the codons in those coding regions. <b><a href="mpep-9020-appx-r.html#d0e333753">37 CFR 1.822(d)</a></b>
                           only requires that where amino acids corresponding to the codons in the coding parts of
                           a nucleotide sequence are depicted, they must be depicted below the corresponding
                           codons. There is absolutely no requirement in the rules to depict coding regions. Nor is
                           there a requirement to separately list the amino acids corresponding to the codons in
                           the coding parts of a nucleotide sequence unless the applicant desires to discuss the
                           amino acids as a separate sequence. That is, when the coding parts of a nucleotide
                           sequence and their corresponding amino acids have been identified, if applicant desires
                           to discuss those amino acids in the coding parts of the nucleotide as a separate
                           sequence, those amino acids must also be set forth as a separate sequence. The separate
                           submission of the amino acid sequence that corresponds to the coding parts of a
                           nucleotide sequence is, however, recommended and encouraged because the amino acid
                           sequence may not be captured in the sequence database if it is only presented in the
                           “Sequence Listing” as a mixed nucleotide and amino acid sequence. 
                        </p>
                     </div>
                     <div class="Section">
                        <h1 class="page-title" id="d0e245637">2423.03
                           &nbsp;&nbsp;Presentation and Enumeration of Sequences  [R-08.2012]
                        </h1>
                        <p id="d0e245641"><b><a href="mpep-9020-appx-r.html#d0e333753">37
                                 CFR 1.822(c)(5)</a></b> provides that nucleotide sequences shall only be
                           represented by a single strand, in the 5′ to 3′ direction, from left to right. That is,
                           double stranded nucleotides shall not be represented in the “Sequence Listing.” A double
                           stranded nucleotide may be represented as two single stranded nucleotides, and any
                           relationship between the two may be shown in the drawings. 
                        </p>
                        <p id="d0e245646">The procedures for presenting and
                           numbering amino acid sequences are set forth in <b><a href="mpep-9020-appx-r.html#d0e333753">37 CFR 1.822(d)</a></b>.
                           Two alternatives are presented for numbering amino acid sequences. Amino acid sequences
                           may be numbered with respect to the identification of the first amino acid of the first
                           mature protein or with respect to the first amino acid appearing at the amino terminal.
                           The enumeration procedure for nucleotides is set forth in <b><a href="mpep-9020-appx-r.html#d0e333753">37 CFR
                                 1.822(c)(6)</a></b>. Sequences that are circular in configuration are
                           intended to be encompassed by these rules, and numbering procedures for them are
                           provided in <b><a href="mpep-9020-appx-r.html#d0e333753">37 CFR 1.822(c)(7) and (d)(4)</a></b>. The
                           numbering procedures set forth in <b><a href="mpep-9020-appx-r.html#d0e333753">37 CFR 1.822(c) and (d)</a></b> are not
                           necessarily intended to be consistent with all currently employed numbering procedures.
                           The objective here is to establish a reasonable numbering procedure that can readily be
                           followed and adhered to. These formatting procedures also reflect those that have been
                           agreed to for electronic data exchange with the JPO and the EPO.
                        </p>
                        <p id="d0e245661">In <b><a href="mpep-9020-appx-r.html#d0e333753">37 CFR
                                 1.822(e)</a></b> the procedures for presenting and numbering hybrid and
                           gapped sequences are set forth. A sequence that is made up of one or more noncontiguous
                           segments of a larger sequence or segments from different sequences, i.e., a hybrid
                           sequence, shall be presented as a separate sequence. A “gap” for the purpose of this
                           section is not intended to embrace a gap or gaps that is/are introduced into the
                           presentation of otherwise continuous sequence information in, e.g., a drawing figure, to
                           show alignments or similarities with other sequences. The “gaps” referred to in this
                           section are gaps representing unknown or undisclosed regions in a sequence between
                           regions that are known or disclosed. In the situation where a contiguous fragment of a
                           sequence that has already been properly set forth in a “Sequence Listing” is discussed
                           and/or claimed, the fragment does not need to be separately included in the “Sequence
                           Listing.” It may be referred to in the specification, claims or drawings as, e.g.,
                           “residues 2 through 33 of SEQ ID NO:12,” assuming that SEQ ID NO:12 has been properly
                           included in the “Sequence Listing.” 
                        </p>
                     </div>
                     <p align="right"><a href="#top">[top]</a></p>
                  </div>
               </div>
               <div>
                  <h1 class="page-title">&nbsp;</h1>
               </div>  </div>
            </div>
         </div>
      </div>
      <div class="yui-b">
         <div id="aside">  <div id="rdms-sub-nav-container" xmlns:bf="http://www.uspto.gov/bf">
            <ul id="sub-nav">
               <li xmlns=""><a href="s2401.html">2401-Introduction</a></li>
               <li xmlns=""><a href="s2402.html">2402-The Deposit Rules</a></li>
               <li xmlns=""><a href="s2403.html">2403-Deposit of Biological Material</a><ul>
                     <li><a href="s2403.html#d0e240728">2403.01-Material Capable of Self- Replication</a></li>
                     <li><a href="s2403.html#d0e240735">2403.02-Plant Material</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2404.html">2404-Need or Opportunity to Make a Deposit</a><ul>
                     <li><a href="s2404.html#d0e240816">2404.01-Biological Material That Is Known and Readily Available to the Public</a></li>
                     <li><a href="s2404.html#d0e240930">2404.02-Biological Material That Can Be Made or Isolated Without Undue Experimentation</a></li>
                     <li><a href="s2404.html#d0e240946">2404.03-Reference to a Deposit in the Specification</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2405.html">2405-Acceptable Depository</a></li>
               <li xmlns=""><a href="s2406.html">2406-Time of Making an Original Deposit</a><ul>
                     <li><a href="s2406.html#d0e241742">2406.01-Description in Application Specification</a></li>
                     <li><a href="s2406.html#d0e241769">2406.02-Deposit After Filing Date - Corroboration</a></li>
                     <li><a href="s2406.html#d0e241779">2406.03-Possible Loss of U.S. Filing Date in Other Countries</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2407.html">2407-Replacement or Supplement of Deposit</a><ul>
                     <li><a href="s2407.html#d0e241898">2407.01-In a Pending Application</a></li>
                     <li><a href="s2407.html#d0e241922">2407.02-After a Patent Has Issued</a></li>
                     <li><a href="s2407.html#d0e241949">2407.03-Failure to Replace</a></li>
                     <li><a href="s2407.html#d0e241964">2407.04-Treatment of Replacement</a></li>
                     <li><a href="s2407.html#d0e241982">2407.05-Exemption From Replacement</a></li>
                     <li><a href="s2407.html#d0e241992">2407.06-Replacement May Not Be Recognized</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2408.html">2408-Term of Deposit</a></li>
               <li xmlns=""><a href="s2409.html">2409-Viability of Deposit</a></li>
               <li xmlns=""><a href="s2410.html">2410-Furnishing of Samples</a><ul>
                     <li><a href="s2410.html#d0e242157">2410.01-Conditions of Deposit</a></li>
                     <li><a href="s2410.html#d0e242206">2410.02-Certification of Statement of Availability of Deposit</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2411.html">2411-Examination Procedures</a><ul>
                     <li><a href="s2411.html#d0e242312">2411.01-Rejections Based on Deposit Issue</a></li>
                     <li><a href="s2411.html#d0e242401">2411.02-Replies to Rejections Based on Deposit Issue</a></li>
                     <li><a href="s2411.html#d0e242424">2411.03-Application in Condition for Allowance Except for Deposit</a></li>
                     <li><a href="s2411.html#d0e242459">2411.04-After a Patent Has Been Granted</a></li>
                     <li><a href="s2411.html#d0e242505">2411.05-Content of Application with Respect to Deposited Material</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2412-2419.html">2412-2419-[Reserved]</a></li>
               <li xmlns=""><a href="s2420.html">2420-The Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures - the Sequence
                     Rules</a></li>
               <li xmlns=""><a href="s2421.html">2421-Overview of the Sequence Rules</a><ul>
                     <li><a href="s2421.html#d0e242552">2421.01-Applications Affected</a></li>
                     <li><a href="s2421.html#d0e242568">2421.02-Summary of the Requirements of the Sequence Rules</a></li>
                     <li><a href="s2421.html#d0e242594">2421.03-Notification of a Failure to Comply</a></li>
                     <li><a href="s2421.html#d0e242622">2421.04-Future Changes to the Sequence Rules</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2422.html">2422-Nucleotide and/or Amino Acid Sequence Disclosures in Patent Applications</a><ul>
                     <li><a href="s2422.html#d0e245121">2422.01-Definitions of Nucleotide and/or Amino Acids for Purpose of Sequence Rules</a></li>
                     <li><a href="s2422.html#d0e245175">2422.02-The Requirement for Exclusive Conformance; Sequences Presented in Drawing Figures</a></li>
                     <li><a href="s2422.html#d0e245191">2422.03-The Requirements for a Sequence Listing and Sequence Identifiers; Sequences Embedded in Application Text; Variants of a Presented
                           Sequence</a></li>
                     <li><a href="s2422.html#d0e245299">2422.04-The Requirement for a Computer Readable Copy of the Official Copy of the Sequence Listing</a></li>
                     <li><a href="s2422.html#d0e245330">2422.05-Reference to Previously Filed Identical Computer Readable Form; Continuing or Derivative Applications; Request for Transfer
                           of Computer Readable Form</a></li>
                     <li><a href="s2422.html#d0e245358">2422.06-Requirement for Statement Regarding Content of Official and Computer Readable Copies of Sequence Listing</a></li>
                     <li><a href="s2422.html#d0e245376">2422.07-Requirements for Compliance, Statements Regarding New Matter, and Sanctions for Failure to Comply</a></li>
                     <li><a href="s2422.html#d0e245454">2422.08-Presumptions Regarding Compliance</a></li>
                     <li><a href="s2422.html#d0e245470">2422.09-Box Sequence; Hand Delivery of Sequence Listings and Computer Readable Forms</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2423.html">2423-Symbols and Format To Be Used for Nucleotide and/or Amino Acid Sequence Data</a><ul>
                     <li><a href="s2423.html#d0e245579">2423.01-Format and Symbols To Be Used in Sequence Listings</a></li>
                     <li><a href="s2423.html#d0e245618">2423.02-Depiction of Coding Regions</a></li>
                     <li><a href="s2423.html#d0e245637">2423.03-Presentation and Enumeration of Sequences</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2424.html">2424-Requirements for Nucleotide and/or Amino Acid Sequences as Part of the Application Papers</a><ul>
                     <li><a href="s2424.html#d0e246252">2424.01-Informational Requirements for the Sequence Listing</a></li>
                     <li><a href="s2424.html#d0e246289">2424.02-Sequence Listing Numeric Identifiers</a></li>
                     <li><a href="s2424.html#d0e246838">2424.03-Additional Miscellaneous Requirements</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2425.html">2425-Form and Format for Nucleotide and/or Amino Acid Sequence Submissions in Computer Readable Form</a></li>
               <li xmlns=""><a href="s2426.html">2426-Amendments to or Replacement of Sequence Listing and Computer Readable Copy Thereof</a></li>
               <li xmlns=""><a href="s2427.html">2427-Form Paragraphs and Notice to Comply</a><ul>
                     <li><a href="s2427.html#d0e247062">2427.01-Form Paragraphs</a></li>
                     <li><a href="s2427.html#d0e247506">2427.02-Notice To Comply</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2428.html">2428-Sample Statements</a></li>
               <li xmlns=""><a href="s2429.html">2429-Helpful Hints for Compliance</a></li>
               <li xmlns=""><a href="s2430.html">2430-PatentIn Information; Utilities Programs; Training</a></li>
               <li xmlns=""><a href="s2431.html">2431-Sample Sequence Listing</a></li>
               <li xmlns=""><a href="s2432-2433.html">2432-2433-[Reserved]</a></li>
               <li xmlns=""><a href="s2434.html">2434-Examination of Patent Applications Claiming Large Numbers of Nucleotide Sequences</a></li>
               <li xmlns=""><a href="s2435.html">2435-Publishing of Patents and Patent Application Publications with Lengthy Sequence Listings</a></li>
            </ul>  </div>
         </div>
      </div>  </div>
      <!-- Footer Navigation: /includes/general/footer2.html -->

<!-- Used in: MPEP, CPC -->

<!-- ID = $Id: footer2.html 3354 2013-04-23 18:43:33Z janaki $ -->

<!-- URL = $URL: https://dev-wmb-svn.etc.uspto.gov/repos/live/active_content/trunk/includes/general/footer2.html $ -->





  <div style="text-align:right"> Last Modified: 

     

    03/27/2014 10:10:34 

  </div>

</div>

</div>

<div id="extra-div-1"> <span/> </div>

<div id="extra-div-2"> <span/> </div>

<div id="extra-div-3"> <span/> </div>

<div id="extra-div-4"> <span/> </div>

<div id="extra-div-5"> <span/> </div>

<div id="extra-div-6"> <span/> </div>



<!-- End of footer2.html -->


   </body>
</html>